Bristol Myers Squibb Company $BMY Shares Sold by Lantz Financial LLC

Key Points

• Lantz Financial LLC reduced its stake in Bristol Myers Squibb by 41.5%, selling 5,621 shares and ending the quarter with 7,937 shares valued at approximately $367,000.
• Institutional investors currently own 76.41% of Bristol Myers Squibb, with other firms, including Brighton Jones LLC and Waverly Advisors LLC, increasing their holdings significantly during the fourth quarter.
• Bristol Myers Squibb reported a quarterly EPS of $1.46, exceeding analyst estimates, and announced a dividend of $0.62 per share to be paid on November 3rd, representing a 5.5% yield.

Lantz Financial LLC decreased its holdings in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 41.5% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,937 shares of the biopharmaceutical company's stock after selling 5,621 shares during the period. Lantz Financial LLC's holdings in Bristol Myers Squibb were worth $367,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of the business. Marcum Wealth LLC increased its position in shares of Bristol Myers Squibb by 1.0% during the first quarter. Marcum Wealth LLC now owns 19,296 shares of the biopharmaceutical company's stock worth $1,177,000 after purchasing an additional 193 shares in the last quarter. Beacon Investment Advisory Services Inc. increased its position in shares of Bristol Myers Squibb by 2.7% during the first quarter. Beacon Investment Advisory Services Inc. now owns 8,063 shares of the biopharmaceutical company's stock worth $492,000 after purchasing an additional 212 shares in the last quarter. 1858 Wealth Management LLC increased its position in shares of Bristol Myers Squibb by 3.6% during the first quarter. 1858 Wealth Management LLC now owns 6,421 shares of the biopharmaceutical company's stock worth $392,000 after purchasing an additional 221 shares in the last quarter. Tompkins Financial Corp increased its position in shares of Bristol Myers Squibb by 2.5% during the first quarter. Tompkins Financial Corp now owns 9,151 shares of the biopharmaceutical company's stock worth $558,000 after purchasing an additional 225 shares in the last quarter. Finally, LS Investment Advisors LLC increased its position in shares of Bristol Myers Squibb by 1.3% during the first quarter. LS Investment Advisors LLC now owns 17,015 shares of the biopharmaceutical company's stock worth $1,038,000 after purchasing an additional 225 shares in the last quarter. Institutional investors own 76.41% of the company's stock.

Insider Activity

In other news, EVP David V. Elkins sold 56,000 shares of the stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the sale, the executive vice president directly owned 167,379 shares of the company's stock, valued at $7,922,048.07. This represents a 25.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.07% of the stock is currently owned by insiders.

Bristol Myers Squibb Price Performance

Shares of BMY stock traded up $0.17 during mid-day trading on Tuesday, hitting $45.15. 4,015,320 shares of the stock were exchanged, compared to its average volume of 12,998,196. The firm has a fifty day moving average of $46.88 and a 200 day moving average of $49.47. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54. Bristol Myers Squibb Company has a 52-week low of $42.96 and a 52-week high of $63.33. The company has a market cap of $91.89 billion, a PE ratio of 18.20, a price-to-earnings-growth ratio of 2.30 and a beta of 0.35.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The business had revenue of $12.27 billion for the quarter, compared to analyst estimates of $11.32 billion. During the same period in the prior year, the company posted $2.07 EPS. The company's revenue for the quarter was up .6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Research analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd will be paid a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 5.5%. The ex-dividend date of this dividend is Friday, October 3rd. Bristol Myers Squibb's dividend payout ratio is presently 100.00%.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on BMY. Citigroup reduced their price target on Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating on the stock in a research report on Friday, August 1st. Daiwa Capital Markets downgraded Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price target on the stock. in a research report on Tuesday, August 5th. Daiwa America downgraded Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 5th. Wall Street Zen downgraded Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. Finally, Morgan Stanley reissued a "hold" rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $56.38.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.